Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Hemorrhage D006470 15 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Hemorrhagic Fever, American D006478 2 associated lipids
Hepatitis, Alcoholic D006519 5 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypercalcemia D006934 13 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hypersensitivity D006967 22 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Hypotension D007022 41 associated lipids
Ileal Diseases D007077 3 associated lipids
Ileitis D007079 2 associated lipids
Immune Complex Diseases D007105 9 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Infertility, Male D007248 11 associated lipids
Inflammation D007249 119 associated lipids
Intestinal Obstruction D007415 6 associated lipids
Ischemia D007511 18 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Klebsiella Infections D007710 7 associated lipids
Leukemia D007938 74 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Leukopenia D007970 9 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lymphoma D008223 18 associated lipids
Malabsorption Syndromes D008286 16 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Medulloblastoma D008527 22 associated lipids
Melanoma D008545 69 associated lipids
Memory Disorders D008569 33 associated lipids
Meningioma D008579 11 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Migraine Disorders D008881 11 associated lipids
Mouth, Edentulous D009066 1 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Multiple Trauma D009104 2 associated lipids
Nasal Polyps D009298 26 associated lipids
Neoplastic Cells, Circulating D009360 5 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Michel L and Dubertret L A simple method for studying chemotaxis, vascular permeability and histological modifications induced by mediators of inflammation in vivo in man. 1985 Br. J. Dermatol. pmid:2990519
Morris HG Mechanisms of glucocorticoid action in pulmonary disease. 1985 Chest pmid:2410202
Bruynzeel PL et al. Exclusive leukotriene C4 synthesis by purified human eosinophils induced by opsonized zymosan. 1985 FEBS Lett. pmid:2995125
Morley J et al. Pharmacology of the late response to allergen and its relevance to asthma prophylaxis. 1985 Int. Arch. Allergy Appl. Immunol. pmid:3924841
Hwang SB et al. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. 1985 Lab. Invest. pmid:3925239
Naccache PH et al. Unique inhibitory profile of platelet activating factor induced calcium mobilization, polyphosphoinositide turnover and granule enzyme secretion in rabbit neutrophils towards pertussis toxin and phorbol ester. 1985 Biochem. Biophys. Res. Commun. pmid:2992480
MacIntyre DE et al. Regulation of platelet cytosolic free calcium by cyclic nucleotides and protein kinase C. 1985 FEBS Lett. pmid:2993027
Bourgain RH et al. The effect of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (paf-acether) on the arterial wall. 1985 Prostaglandins pmid:3931178
Hayashi H et al. Activation of guinea pig peritoneal macrophages by platelet activating factor (PAF) and its agonists. 1985 J. Biochem. pmid:2993272
Avdonin PV et al. Stimulation of high-affinity hormone-sensitive GTPase of human platelets by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphocholine (platelet activating factor). 1985 Biochem. Biophys. Res. Commun. pmid:2994653
Ribbes G et al. Evidence that biosynthesis of platelet-activating factor (paf-acether) by human neutrophils occurs in an intracellular membrane. 1985 FEBS Lett. pmid:3932094
Maridonneau-Parini I et al. Desensitization to PAF-induced bronchoconstriction and to activation of alveolar macrophages by repeated inhalations of PAF in the guinea pig. 1985 Biochem. Biophys. Res. Commun. pmid:2994661
García-Sáinz JA and Hernández-Sotomayor SM Stimulation of hepatic glycogenolysis by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) via cyclooxygenase products. 1985 Biochem. Biophys. Res. Commun. pmid:3933497
Zukowska-Grojec Z et al. The adrenergic system and the cardiovascular effects of platelet activating factor (1-0-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) in SHR and WKY rats. 1985 Clin Exp Hypertens A pmid:2994912
Shen TY et al. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor. 1985 Int J Tissue React pmid:2997065
Sánchez Crespo M et al. Synthesis of platelet-activating factor from human polymorphonuclear leukocytes: regulation and pharmacological approaches. 1985 Int J Tissue React pmid:2997066
Barnes PJ Mediators and asthma. 1985 Br J Hosp Med pmid:3936563
Proll MA et al. Phosphatidate and monooleylphosphatidate inhibition of fibroblast adenylate cyclase is mediated by the inhibitory coupling protein, Ni. 1985 Mol. Pharmacol. pmid:2997592
Hemmendinger S et al. [Physiology of the interactions of blood and the blood vessel wall. Role of pharmacologically active lipids]. 1985 Arch Mal Coeur Vaiss pmid:3938941
Iñarrea P et al. Synthesis of PAF-acether and blood volume changes in gram-negative sepsis. 1985 Immunopharmacology pmid:3886598
Lad PM et al. Platelet-activating factor mediated effects on human neutrophil function are inhibited by pertussis toxin. 1985 Biochem. Biophys. Res. Commun. pmid:2990462
Sánchez-Crespo M et al. Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of paf-acether. 1985 Immunopharmacology pmid:3840779
Foa R et al. Release of platelet-activating factor in human leukemia. 1985 Cancer Res. pmid:3861246
Otsuka A et al. Hypotensive mechanism of acetyl glyceryl ether phosphorylcholine (AGEPC) in dogs. Effects on hemodynamics and humoral factors. 1985 Prostaglandins Leukot Med pmid:3862138
Teng CM et al. Action mechanism of the platelet aggregation inducer and inhibitor from Echis carinatus snake venom. 1985 Biochim. Biophys. Acta pmid:3926005
Ostermann G et al. Platelet-stimulating and membranolytic properties of racemic PAF-acether and analogues. 1985 Biomed. Biochim. Acta pmid:4004829
Touqui L et al. Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when the degrading enzyme acetyl hydrolase is blocked. 1985 Biochem. J. pmid:4052028
Satouchi K et al. Evidence for production of 1-acyl-2-acetyl-sn-glyceryl-3-phosphorylcholine concomitantly with platelet-activating factor. 1985 Biochem. Biophys. Res. Commun. pmid:4004866
Apprill P et al. Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors. 1985 Circulation pmid:2988822
MacIntyre DE et al. Tumour-promoting phorbol esters inhibit agonist-induced phosphatidate formation and Ca2+ flux in human platelets. 1985 FEBS Lett. pmid:2981715
Cordón-Cardó C [The barley cell or mastocyte: cellular and molecular biology]. 1985 Med Clin (Barc) pmid:2580196
Disselnkötter H et al. [Synthesis of phosphono analogs of 2-O-acetyl-1-O-hexadecyl(octadecyl)-sn-3-glycerylphosphorylcholine (platelet-activating factor)]. 1985 Arch. Pharm. (Weinheim) pmid:4051690
Ogunbiyi PO and Eyre P Pharmacological studies of pulmonary anaphylaxis in vitro: a review. 1985 Agents Actions pmid:2420161
Robinson M and Snyder F Metabolism of platelet-activating factor by rat alveolar macrophages: lyso-PAF as an obligatory intermediate in the formation of alkylarachidonoyl glycerophosphocholine species. 1985 Biochim. Biophys. Acta pmid:4052436
Kozlov VK et al. [Characteristics of the activation of rabbit platelets induced by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activation factor)]. 1985 Biull Eksp Biol Med pmid:4052603
Page CP et al. Properties of PAF-acether appropriate to a mediator of the inflammatory aspects of asthma. 1985 Int J Tissue React pmid:4055261
Wardlow ML Rapid isocratic procedure for the separation of platelet-activating factor from phospholipids in human saliva by high-performance liquid chromatography. 1985 J. Chromatogr. pmid:4055961
Hubbard JW et al. Cardiac output and peripheral vascular resistance during intravenous infusion of 1-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine in conscious normotensive and spontaneously hypertensive rats. 1985 Res. Commun. Chem. Pathol. Pharmacol. pmid:4059660
Imbs AB et al. [Synthesis of a fluorescently-labeled platelet activating factor]. 1985 Bioorg. Khim. pmid:4062993
Tokumura A et al. Gas chromatographic-mass spectrometric analysis of biologically active phospholipids having an sn-2-acetyl group. 1985 J. Chromatogr. pmid:4066848
Meloni Bruneri LH and Barbieri D [Platelet aggregation after the reduction of nitro-blue tetrazolium by eosinophils]. 1985 Sangre (Barc) pmid:4071355
Vanhoutte PM and Houston DS Platelets, endothelium, and vasospasm. 1985 Circulation pmid:3861273
Tan EL and Snyder F Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. 1985 Thromb. Res. pmid:4024051
Weisman SM et al. Platelet-activating factor is a potent stimulus for renal prostaglandin synthesis: possible significance in unilateral ureteral obstruction. 1985 J. Pharmacol. Exp. Ther. pmid:3862805
Morley J et al. PAF and airway hyperreactivity. 1985 Lancet pmid:2863479
Morley J et al. Platelets in asthma. 1985 Lancet pmid:2863708
Orlov SM et al. [Histamine release from human leukocytes after treatment with 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) and its structural analogs]. 1985 Biokhimiia pmid:2408682
Hallam TJ and Rink TJ Agonists stimulate divalent cation channels in the plasma membrane of human platelets. 1985 FEBS Lett. pmid:2408921
O'Neill C et al. Maternal recognition of pregnancy prior to implantation: methods for monitoring embryonic viability in vitro and in vivo. 1985 Ann. N. Y. Acad. Sci. pmid:2409860
Sage SO and Rink TJ Inhibition by forskolin of cytosolic calcium rise, shape change and aggregation in quin2-loaded human platelets. 1985 FEBS Lett. pmid:2410292